跳至主要内容
临床试验/TCTR20180823002
TCTR20180823002已完成3 期

Effect of Vernonia cinerea lozenges as a smoking cessation aid in patients with non-communicable diseases.

TOBACCO CONTROL RESEARCH AND KNOWLEDGE MANAGEMENT CENTER0 个研究点目标入组 93 人开始时间: 2018年8月23日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
93

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • Age at least 18 years old
  • - Have at least 1 underlying non-communicable disease include hypertension, diabetes, dyslipidemia, cardiovascular diseases, cerebrovascular diseases, stable asthma, COPD stage A-C according to GOLD guideline, chronic kidney diseases
  • - Smoke 10 cigarettes or over per day at least 1 month prior to study
  • - Desired to quit smoking
  • - Consent to participate in study

排除标准

  • - Renal dysfunction (GFR < 30 ml/mins/1.73m2)
  • - Liver dysfunction (Child-Pugh score C)
  • - Hyperkalemia (serum potassium <=5 mEq/L)
  • - Documented of active depression or psychosis
  • - Active cancer
  • - History of acute coronary syndrome in previous 4 weeks
  • - Known case of pregnancy or lactation
  • - Use other tobacco products or other addictive substances except alcohol
  • - Use other smoking cessation drugs

研究者

发起方
TOBACCO CONTROL RESEARCH AND KNOWLEDGE MANAGEMENT CENTER

相似试验